J&A to Add Monoclonal Antibody Treatments to FEMA's National Vaccination Contract

This is a class justification & approval (J&A) for the Department of Homeland Security, Federal Emergency Management Agency (FEMA) in accordance with (a) FAR 6.303-1(d) and 6.302-2, Unusual and Compelling Urgency.

This J&A is related to solicitation # 70FB8021R00000001 - Medical Personnel for COVID-19 Vaccination Support
This class J&A applies to the following IDIQ contracts:

• OptumServe Health Services, Inc., 328 Front Street South, La Crosse, WI 546014 (Contract # 70FB8021D00000002) and
• AMN Health Inc., 12400 High Bluff Dr, San Diego, CA 92130 (Contract# 70FB8021D00000003)

Background:
FEMA previously competed and awarded the National Clinical Vaccination (NCV) contract which was recently awarded on May 15, 2021. The NCV staffing contract is uniquely postured to administer the monoclonal antibody (mAb) treatments to prevent mild and moderate COVID-19 cases from progressing to hospitalization. This procedure is classified as a passive vaccination and currently given subcutaneously
(by injection under the skin) or by IV.  There are Labor categories identified in the Statement of Work are capable of administering the mAb treatments to individual state health department direction. The urgent and compelling need to alleviate suffering and stem the progression of COVID-19 warrant the use of this contract for mAb treatments.

See attached J&A for further details.

Awarded contract 70FB8021D00000002 to unknown vendor for unknown amount on 2021-05-14.